Retinopathy of Prematurity (ROP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
_page-0001.jpg)
Retinopathy of prematurity (ROP) is an eye disease that affects some premature babies born before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a condition that affects the retina, the tissue at the back of the eye. The retina detects light and sends signals to the brain, allowing you to see. Unwanted blood vessels grow on the baby's retina due to ROP. These blood vessels can later cause serious eye and vision problems. Sometimes immediate treatment is required to avoid blindness. If not treated promptly, the child may suffer from severe permanent vision loss or even go blind. Most babies with ROP normally see for their age. Vision is only threatened when ROP progresses to the most severe stages. Fortunately, the majority of ROP resolves without causing vision loss. The most important factors in preventing ROP-related vision loss are effective screening and timely treatment (when indicated. Birth weight and gestational age are the most critical risk factors for developing severe ROP. Other factors associated with the presence of ROP include anemia, poor weight gain, blood transfusion, respiratory distress, breathing difficulties and the infant's overall health. There is active research into the correlation between levels of growth factors in the blood and ROP. Close monitoring has reduced the impact of oxygen use as a risk factor for developing ROP. Light levels do not affect the severity of ROP.
·
The incidence of ROP is approximately 50% to
60% in preterm infants with a birth weight (BW) < 1500 g, while the rate of
progression to severe ROP (Stages 3–5) has been reported to be approximately
15%.
Thelansis’s “Retinopathy of
Prematurity (ROP) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Retinopathy
of Prematurity (ROP) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Retinopathy of Prematurity (ROP) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Retinopathy of Prematurity (ROP) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment